BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 19888874)

  • 21. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer.
    Raez LE; Kobina S; Santos ES
    Clin Lung Cancer; 2010 Jan; 11(1):18-24. PubMed ID: 20085863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.
    Smith JW; McIntyre KJ; Acevedo PV; Encarnacion CA; Tedesco KL; Wang Y; Asmar L; O'Shaughnessy JA
    Breast Cancer Res Treat; 2009 Nov; 118(2):361-7. PubMed ID: 19459042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A better platinum-based anticancer drug yet to come?
    Olszewski U; Hamilton G
    Anticancer Agents Med Chem; 2010 May; 10(4):293-301. PubMed ID: 20187870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
    Oh WK; Tay MH; Huang J
    Cancer; 2007 Feb; 109(3):477-86. PubMed ID: 17186531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxaliplatin: a review of preclinical and clinical studies.
    Raymond E; Chaney SG; Taamma A; Cvitkovic E
    Ann Oncol; 1998 Oct; 9(10):1053-71. PubMed ID: 9834817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Satraplatin for hormone-refractory prostate cancer.
    Kerr C
    Lancet Oncol; 2007 Apr; 8(4):290. PubMed ID: 17431954
    [No Abstract]   [Full Text] [Related]  

  • 27. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platinum anticancer drugs. From serendipity to rational design.
    Monneret C
    Ann Pharm Fr; 2011 Nov; 69(6):286-95. PubMed ID: 22115131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.
    Galsky MD; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
    Ann Oncol; 2012 Apr; 23(4):1037-44. PubMed ID: 21828377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
    Stordal B; Pavlakis N; Davey R
    Cancer Treat Rev; 2007 Jun; 33(4):347-57. PubMed ID: 17383100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.
    Armstrong AJ; George DJ
    Ther Clin Risk Manag; 2007 Oct; 3(5):877-83. PubMed ID: 18473011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New-generation platinum agents for solid tumors.
    Shah N; Dizon DS
    Future Oncol; 2009 Feb; 5(1):33-42. PubMed ID: 19243296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
    Samimi G; Howell SB
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance.
    Kalimutho M; Minutolo A; Grelli S; Formosa A; Sancesario G; Valentini A; Federici G; Bernardini S
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1299-312. PubMed ID: 20734047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New-generation platinum drugs in the treatment of cisplatin-resistant cancers.
    McKeage MJ
    Expert Opin Investig Drugs; 2005 Aug; 14(8):1033-46. PubMed ID: 16050795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New platinum antitumor complexes.
    Kelland LR
    Crit Rev Oncol Hematol; 1993 Dec; 15(3):191-219. PubMed ID: 8142057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.
    Marcus L; Murphy R; Fox E; McCully C; Cruz R; Warren KE; Meyer T; McNiff E; Balis FM; Widemann BC
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):247-52. PubMed ID: 21706317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The emerging role of oxaliplatin in the treatment of gastric cancer.
    Zaniboni A; Meriggi F
    J Chemother; 2005 Dec; 17(6):656-62. PubMed ID: 16433197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Oxaliplatin: a first DACH-platinum in oncology].
    Laadem A; Cvitkovic E
    Bull Cancer; 2001 Aug; 88 Spec No():S9-13. PubMed ID: 11567908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.